{"gene":"AREL1","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":2013,"finding":"AREL1 is a cytosolic HECT-family E3 ubiquitin ligase that interacts with and ubiquitinates IAP antagonists SMAC, HtrA2, and ARTS specifically after apoptotic stimulation releases them from mitochondria into the cytosol, promoting their degradation and thereby suppressing caspase-3 cleavage, XIAP degradation, and apoptosis.","method":"Co-immunoprecipitation, ubiquitination assays in cells, siRNA knockdown with apoptosis readouts (caspase-3 cleavage, XIAP degradation), subcellular fractionation/localization","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus functional knockdown with defined apoptosis phenotype, single lab, multiple orthogonal methods","pmids":["23479728"],"is_preprint":false},{"year":2015,"finding":"AREL1 HECT E3 ligase preferentially assembles K33- and K11-linked polyubiquitin chains in vitro.","method":"In vitro ubiquitination assay using purified AREL1 combined with linkage-selective DUBs; mass spectrometry to confirm chain linkage","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with purified enzyme, confirmed by independent study (PMID:25752577), replicated across two labs","pmids":["25723849","25752577"],"is_preprint":false},{"year":2015,"finding":"AREL1 assembles K11/K33-linked ubiquitin chains, and in combination with linkage-selective DUBs can be used to generate pure K33-linked chains; these chains adopt an open, dynamic solution conformation.","method":"In vitro ubiquitination assay, mass spectrometry for linkage determination, NMR solution studies","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with purified components, replicated across two labs (PMID:25723849)","pmids":["25752577"],"is_preprint":false},{"year":2016,"finding":"AREL1 (FIEL1/KIAA0317) ubiquitinates the SUMO E3 ligase PIAS4, targeting it for proteasomal degradation via a double-locking mechanism requiring PKCζ-mediated phosphorylation of PIAS4 and GSK3β-mediated phosphorylation of FIEL1, thereby potentiating TGF-β signaling and promoting pulmonary fibrosis.","method":"Co-immunoprecipitation, ubiquitination assays, phosphorylation assays with kinase inhibitors/knockdown, overexpression and knockdown in cells and bleomycin murine fibrosis model","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, in vivo mouse model, site-specific phosphorylation mechanism defined, small molecule inhibitor validation, single lab but multiple orthogonal methods","pmids":["27162139"],"is_preprint":false},{"year":2019,"finding":"KIAA0317 (AREL1) mediates the ubiquitination and proteasomal degradation of SOCS2, exacerbating proinflammatory cytokine signaling; KIAA0317 knockout mice are resistant to LPS-induced pulmonary inflammation, and a small molecule inhibitor (BC-1365) prevents SOCS2 degradation and attenuates lung inflammation in vivo.","method":"Co-immunoprecipitation, ubiquitination assays, KIAA0317 knockout mice, LPS and P. aeruginosa lung inflammation models, small molecule inhibitor","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO mouse model with defined inflammatory phenotype, in vivo pharmacological validation, multiple orthogonal methods, single lab","pmids":["31578312"],"is_preprint":false},{"year":2019,"finding":"Crystal structure of the extended HECT domain of AREL1 (aa 436–823) at 2.4 Å resolution reveals an inverted T-shaped bilobed conformation with a unique loop (aa 567–573) absent in all other HECT members; the N-terminal extended region (aa 436–482) is indispensable for HECT domain stability and activity. AREL1 ubiquitinates SMAC primarily on Lys62 and Lys191. The AREL1 HECT domain assembles K33-, K48-, and K63-linked chains; E701A substitution increases autopolyubiquitination and SMAC ubiquitination, while deletion of the C-terminal three residues abrogates autoubiquitination and reduces SMAC ubiquitination.","method":"X-ray crystallography (2.4 Å HECT domain; 2.8 Å SMAC tetramer), in vitro ubiquitination assays, active-site mutagenesis (E701A, C-terminal deletion), ubiquitin variant inhibitor assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus in vitro reconstitution plus active-site mutagenesis in a single study","pmids":["31732561"],"is_preprint":false},{"year":2021,"finding":"AREL1 interacts with Metaxin 2 (MTX2) via the C-terminal domain of MTX2 (distinct from the N-terminal domain that binds MTX1) and ubiquitinates MTX2, promoting its proteasomal degradation; catalytically inactive AREL1-C790A does not degrade MTX2. By degrading MTX2, AREL1 inhibits TNF-induced necroptosis.","method":"Co-immunoprecipitation with domain-mapping constructs, AREL1 catalytic mutant (C790A), siRNA knockdown, necroptosis assay (TNF stimulation)","journal":"Experimental and therapeutic medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — catalytic mutant used to confirm E3 dependence, domain-mapping Co-IP, single lab","pmids":["34584540"],"is_preprint":false},{"year":2023,"finding":"AREL1 and TRIP12 E3 ligases, together with UBE2L3, add K27-, K29-, and K33-linked polyubiquitin chains to pro-IL-1β, promoting its proteasomal degradation and thereby limiting inflammasome-driven mature IL-1β production and neutrophilic inflammation.","method":"RNAi screen, ubiquitination assays, Ube2l3 knockout mice, macrophage inflammasome activation assays, mass spectrometry for chain linkage","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — unbiased RNAi screen, in vivo KO mouse model, mass spectrometry chain-linkage determination, multiple orthogonal methods","pmids":["37474493"],"is_preprint":false},{"year":2023,"finding":"KIAA0317 (AREL1) ubiquitinates SOCS1 and promotes its proteasomal degradation, thereby dysregulating JAK/STAT inflammatory signaling in the colon; modulation of SOCS1 protein levels markedly affects colonic inflammatory responses.","method":"Co-immunoprecipitation, ubiquitination assays, protein-protein interaction domain characterization, siRNA knockdown with JAK/STAT signaling readouts","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with mechanism characterization, functional signaling readout, single lab","pmids":["36938956"],"is_preprint":false},{"year":2023,"finding":"AREL1 interacts with SMAC in TGF-β-treated HUVECs and its overexpression inhibits caspase-3 and caspase-9 activation and apoptosis; miR-320b suppresses AREL1 expression, and AREL1 overexpression rescues miR-320b-induced apoptosis.","method":"Co-immunoprecipitation, overexpression, caspase activity assays, miRNA mimic/inhibitor transfection in HUVECs","journal":"Journal of biochemical and molecular toxicology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP and overexpression experiment, single lab, no mutagenesis","pmids":["37522329"],"is_preprint":false},{"year":2025,"finding":"ER-resident AREL1 establishes membrane contacts between the ER and lysosomes by directly interacting with the Voa subunit of V-ATPase. AREL1 catalyzes K33-linked polyubiquitylation of the V-ATPase V1B2 subunit, inducing its binding to perinuclear ER-localized UBAC2, thereby promoting perinuclear lysosome clustering, lysosomal acidification, and degradative capacity. Loss of AREL1 increases peripheral lysosomes with partially assembled V-ATPase, elevated luminal pH, and reduced degradation. Arel1 knockout mice develop age-dependent Purkinje cell loss, ataxia, motor impairment, and lysosomal dysfunction (lipofuscin accumulation). The deubiquitylase ZRANB1 antagonizes AREL1-mediated V1B2 ubiquitylation.","method":"Co-immunoprecipitation, in vitro ubiquitination assays with linkage identification, live-cell imaging and fractionation for lysosome positioning, lysosomal pH measurements, Arel1 knockout mice with behavioral phenotyping and histology, ZRANB1 knockdown","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods including in vitro ubiquitination, structural contacts, KO mouse model with defined neurological phenotype, identification of writer-eraser pair (AREL1/ZRANB1), single study with comprehensive mechanistic validation","pmids":["41331534"],"is_preprint":false}],"current_model":"AREL1 is an ER-resident HECT E3 ubiquitin ligase that preferentially assembles K33- and K11-linked (and also K27/K29) polyubiquitin chains on diverse substrates including IAP antagonists (SMAC, HtrA2, ARTS), PIAS4, SOCS1, SOCS2, MTX2, pro-IL-1β, and the V-ATPase V1B2 subunit, thereby suppressing apoptosis, modulating cytokine/TGF-β signaling, limiting inflammasome-driven inflammation, and—via a newly defined AREL1-UBAC2-V-ATPase axis—controlling perinuclear lysosomal positioning and acidification that is required for Purkinje cell survival in vivo."},"narrative":{"mechanistic_narrative":"AREL1 is a HECT-family E3 ubiquitin ligase that preferentially assembles non-canonical K33- and K11-linked (and also K27/K29) polyubiquitin chains to control apoptosis, inflammatory signaling, and lysosomal organization [PMID:25723849, PMID:25752577]. Crystallographic analysis of its extended HECT domain reveals an inverted T-shaped bilobed fold with a unique loop absent from other HECT members and an N-terminal extension required for catalytic activity, with catalysis depending on its C-terminal active-site residues [PMID:31732561]. Its earliest defined role is anti-apoptotic: upon apoptotic stimulation, AREL1 binds and ubiquitinates the cytosolic IAP antagonists SMAC, HtrA2, and ARTS to drive their degradation, thereby blocking caspase-3 activation [PMID:23479728, PMID:31732561]. AREL1 additionally degrades regulatory substrates across signaling pathways—PIAS4 to potentiate TGF-β signaling and pulmonary fibrosis [PMID:27162139], SOCS1 and SOCS2 to amplify JAK/STAT and proinflammatory cytokine signaling [PMID:31578312, PMID:36938956], MTX2 to restrain TNF-induced necroptosis [PMID:34584540], and pro-IL-1β (with TRIP12 and UBE2L3) to limit inflammasome-driven inflammation [PMID:37474493]. As an ER-resident ligase, AREL1 establishes ER–lysosome contacts via the V-ATPase Voa subunit and K33-ubiquitinates the V1B2 subunit, recruiting UBAC2 to promote perinuclear lysosome clustering, V-ATPase assembly, and acidification; this activity, antagonized by the deubiquitylase ZRANB1, is required for Purkinje cell survival, as Arel1 knockout mice develop age-dependent ataxia and lysosomal dysfunction [PMID:41331534].","teleology":[{"year":2013,"claim":"Established AREL1 as a functional E3 ligase with a defined biological output by showing it targets IAP antagonists for degradation to suppress apoptosis.","evidence":"Co-IP, cellular ubiquitination assays, and siRNA knockdown with caspase-3/XIAP apoptosis readouts","pmids":["23479728"],"confidence":"Medium","gaps":["Chain linkage type not yet defined","Ubiquitination sites on substrates not mapped","Single lab, no structural basis"]},{"year":2015,"claim":"Defined the biochemical signature of AREL1 by demonstrating it preferentially builds non-canonical K33- and K11-linked chains, distinguishing it from canonical degradative ligases.","evidence":"In vitro reconstitution with purified enzyme, linkage-selective DUBs, mass spectrometry, and NMR of chain conformation; replicated across two labs","pmids":["25723849","25752577"],"confidence":"High","gaps":["Physiological substrates of K33/K11 chains not linked to specific outcomes here","Connection between linkage type and proteasomal fate unresolved"]},{"year":2016,"claim":"Extended AREL1 beyond apoptosis by showing it degrades PIAS4 through a phosphorylation-gated double-lock mechanism to potentiate TGF-β-driven fibrosis.","evidence":"Co-IP, ubiquitination and kinase-dependent phosphorylation assays, bleomycin murine fibrosis model with small-molecule inhibitor","pmids":["27162139"],"confidence":"High","gaps":["Chain linkage on PIAS4 not specified","Generalizability of phospho-gating to other substrates unknown"]},{"year":2019,"claim":"Showed AREL1 amplifies inflammatory signaling by degrading SOCS2, and that genetic or pharmacological inhibition is protective in vivo, establishing therapeutic relevance.","evidence":"Co-IP, ubiquitination assays, KIAA0317 knockout mice in LPS/P. aeruginosa lung inflammation models, BC-1365 inhibitor","pmids":["31578312"],"confidence":"High","gaps":["Linkage type on SOCS2 not defined","Whether SOCS2 degradation is the sole driver of the inflammatory phenotype unclear"]},{"year":2019,"claim":"Provided the structural basis for AREL1 catalysis, identifying a unique HECT-domain loop, an essential N-terminal extension, and the SMAC ubiquitination sites and active-site residues.","evidence":"X-ray crystallography of HECT domain and SMAC tetramer, active-site mutagenesis (E701A, C-terminal deletion), ubiquitin-variant inhibitor assay","pmids":["31732561"],"confidence":"High","gaps":["Full-length structure including N-terminal substrate-recognition region not resolved","Structural determinant of K33/K11 linkage selectivity not defined"]},{"year":2021,"claim":"Added necroptosis control to AREL1's repertoire by showing catalysis-dependent degradation of MTX2 restrains TNF-induced necroptosis.","evidence":"Domain-mapping Co-IP, catalytic mutant (C790A), siRNA knockdown, TNF necroptosis assay","pmids":["34584540"],"confidence":"Medium","gaps":["In vivo relevance not tested","Chain linkage on MTX2 not characterized"]},{"year":2023,"claim":"Demonstrated AREL1 acts as a multi-ligase that, with TRIP12 and UBE2L3, K27/K29/K33-ubiquitinates pro-IL-1β to dampen inflammasome output, and separately degrades SOCS1 to dysregulate colonic JAK/STAT signaling.","evidence":"RNAi screen, ubiquitination assays with MS linkage determination, Ube2l3 knockout mice, macrophage inflammasome assays; Co-IP and JAK/STAT readouts for SOCS1","pmids":["37474493","36938956"],"confidence":"High","gaps":["Relative contributions of AREL1 versus TRIP12 to pro-IL-1β turnover not partitioned","SOCS1 study is single-lab Medium-confidence without in vivo model"]},{"year":2025,"claim":"Redefined AREL1 as an ER-resident organizer of ER–lysosome contacts, linking its K33-ubiquitination of V-ATPase V1B2 to lysosome positioning, acidification, and Purkinje cell survival.","evidence":"Co-IP, in vitro ubiquitination with linkage ID, live-cell imaging/fractionation for lysosome positioning, lysosomal pH measurement, Arel1 knockout mice with behavior and histology, ZRANB1 knockdown","pmids":["41331534"],"confidence":"High","gaps":["Mechanism by which V1B2 ubiquitination drives UBAC2 binding and clustering at atomic level unresolved","Relationship between this ER-resident pool and prior cytosolic/apoptotic roles unclear","Whether neurodegeneration is purely lysosomal or involves other substrates not established"]},{"year":null,"claim":"How AREL1 selects among its many substrates, and how its non-canonical chain linkages dictate proteasomal degradation versus signaling/contact-site assembly, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying substrate-recognition logic established across SMAC, PIAS4, SOCS1/2, MTX2, pro-IL-1β, and V1B2","Functional distinction between K33 chains that target degradation versus those that nucleate ER-lysosome contacts unclear","Reconciliation of cytosolic versus ER-resident localization across studies not addressed"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[0,1,3,5,10]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,3,6,7,10]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[10]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,6]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,7,8]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,8]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[1,5]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[10]}],"complexes":[],"partners":["SMAC","PIAS4","SOCS1","SOCS2","MTX2","UBAC2","ZRANB1","TRIP12"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O15033","full_name":"Apoptosis-resistant E3 ubiquitin protein ligase 1","aliases":["Apoptosis-resistant HECT-type E3 ubiquitin transferase 1"],"length_aa":823,"mass_kda":94.2,"function":"E3 ubiquitin-protein ligase that catalyzes 'Lys-11'- or 'Lys-33'-linked polyubiquitin chains, with some preference for 'Lys-33' linkages (PubMed:25752577). E3 ubiquitin-protein ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates (PubMed:23479728, PubMed:31578312). Ubiquitinates SEPTIN4, DIABLO/SMAC and HTRA2 in vitro (PubMed:23479728). Modulates pulmonary inflammation by targeting SOCS2 for ubiquitination and subsequent degradation by the proteasome (PubMed:31578312)","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/O15033/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/AREL1","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/AREL1","total_profiled":1310},"omim":[{"mim_id":"615380","title":"APOPTOSIS-RESISTANT E3 UBIQUITIN PROTEIN LIGASE 1; AREL1","url":"https://www.omim.org/entry/615380"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/AREL1"},"hgnc":{"alias_symbol":["FIEL1"],"prev_symbol":["KIAA0317"]},"alphafold":{"accession":"O15033","domains":[{"cath_id":"2.60.40.10","chopping":"56-158","consensus_level":"high","plddt":88.4776,"start":56,"end":158},{"cath_id":"2.60.40.10","chopping":"166-276","consensus_level":"high","plddt":87.3723,"start":166,"end":276},{"cath_id":"2.30.29.30","chopping":"280-306_348-432","consensus_level":"high","plddt":87.3884,"start":280,"end":432},{"cath_id":"3.90.1750.10","chopping":"452-617_653-701","consensus_level":"high","plddt":89.9386,"start":452,"end":701},{"cath_id":"3.30.2410.10","chopping":"708-815","consensus_level":"high","plddt":85.5599,"start":708,"end":815}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O15033","model_url":"https://alphafold.ebi.ac.uk/files/AF-O15033-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O15033-F1-predicted_aligned_error_v6.png","plddt_mean":83.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=AREL1","jax_strain_url":"https://www.jax.org/strain/search?query=AREL1"},"sequence":{"accession":"O15033","fasta_url":"https://rest.uniprot.org/uniprotkb/O15033.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O15033/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O15033"}},"corpus_meta":[{"pmid":"25752577","id":"PMC_25752577","title":"Assembly and specific recognition of k29- and k33-linked polyubiquitin.","date":"2015","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/25752577","citation_count":176,"is_preprint":false},{"pmid":"25723849","id":"PMC_25723849","title":"Assembly and structure of Lys33-linked polyubiquitin reveals distinct conformations.","date":"2015","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/25723849","citation_count":63,"is_preprint":false},{"pmid":"28356075","id":"PMC_28356075","title":"Genome-wide association study and accuracy of genomic prediction for teat number in Duroc pigs using genotyping-by-sequencing.","date":"2017","source":"Genetics, selection, evolution : GSE","url":"https://pubmed.ncbi.nlm.nih.gov/28356075","citation_count":43,"is_preprint":false},{"pmid":"23479728","id":"PMC_23479728","title":"Identification of a novel anti-apoptotic E3 ubiquitin ligase that ubiquitinates antagonists of inhibitor of apoptosis proteins SMAC, HtrA2, and ARTS.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23479728","citation_count":40,"is_preprint":false},{"pmid":"33607149","id":"PMC_33607149","title":"Exploring the \"Other\" subfamily of HECT E3-ligases for therapeutic intervention.","date":"2021","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/33607149","citation_count":34,"is_preprint":false},{"pmid":"27162139","id":"PMC_27162139","title":"Ubiquitin E3 ligase FIEL1 regulates fibrotic lung injury through SUMO-E3 ligase PIAS4.","date":"2016","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27162139","citation_count":33,"is_preprint":false},{"pmid":"32151281","id":"PMC_32151281","title":"Epigenetic modulation of AREL1 and increased HLA expression in brains of multiple system atrophy patients.","date":"2020","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/32151281","citation_count":24,"is_preprint":false},{"pmid":"37474493","id":"PMC_37474493","title":"IL-1β turnover by the UBE2L3 ubiquitin conjugating enzyme and HECT E3 ligases limits inflammation.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37474493","citation_count":21,"is_preprint":false},{"pmid":"33313884","id":"PMC_33313884","title":"Insights from the genetic characterization of central precocious puberty associated with multiple anomalies.","date":"2021","source":"Human reproduction (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/33313884","citation_count":21,"is_preprint":false},{"pmid":"34784951","id":"PMC_34784951","title":"Knockdown of circ-FURIN suppresses the proliferation and induces apoptosis of granular cells in polycystic ovary syndrome via miR-195-5p/BCL2 axis.","date":"2021","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/34784951","citation_count":20,"is_preprint":false},{"pmid":"31578312","id":"PMC_31578312","title":"KIAA0317 regulates pulmonary inflammation through SOCS2 degradation.","date":"2019","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/31578312","citation_count":18,"is_preprint":false},{"pmid":"31732561","id":"PMC_31732561","title":"Structural insights into a HECT-type E3 ligase AREL1 and its ubiquitination activities in vitro.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31732561","citation_count":15,"is_preprint":false},{"pmid":"25045014","id":"PMC_25045014","title":"A panel of protein markers for the early detection of lung cancer with bronchial brushing specimens.","date":"2014","source":"Cancer cytopathology","url":"https://pubmed.ncbi.nlm.nih.gov/25045014","citation_count":14,"is_preprint":false},{"pmid":"39994458","id":"PMC_39994458","title":"Cross-ancestry genome-wide association study and systems-level integrative analyses implicate new risk genes and therapeutic targets for depression.","date":"2025","source":"Nature human behaviour","url":"https://pubmed.ncbi.nlm.nih.gov/39994458","citation_count":9,"is_preprint":false},{"pmid":"27658114","id":"PMC_27658114","title":"Therapeutic targets in fibrotic pathways.","date":"2016","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/27658114","citation_count":7,"is_preprint":false},{"pmid":"34584540","id":"PMC_34584540","title":"AREL1 E3 ubiquitin ligase inhibits TNF-induced necroptosis via the ubiquitination of MTX2.","date":"2021","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34584540","citation_count":6,"is_preprint":false},{"pmid":"36003650","id":"PMC_36003650","title":"Downregulation of growth plate genes involved with the onset of femoral head separation in young broilers.","date":"2022","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/36003650","citation_count":6,"is_preprint":false},{"pmid":"37814452","id":"PMC_37814452","title":"Genome-wide association study using a single-step approach for teat number in Duroc, Landrace and Yorkshire pigs in Korea.","date":"2023","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37814452","citation_count":6,"is_preprint":false},{"pmid":"36938956","id":"PMC_36938956","title":"KIAA0317 regulates SOCS1 stability to ameliorate colonic inflammation.","date":"2023","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/36938956","citation_count":4,"is_preprint":false},{"pmid":"37522329","id":"PMC_37522329","title":"AREL1 resists the apoptosis induced by TGF-β by inhibiting SMAC in vascular endothelial cells.","date":"2023","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/37522329","citation_count":4,"is_preprint":false},{"pmid":"39872979","id":"PMC_39872979","title":"Neuroinflammation mediates the progression of neonate hypoxia-ischemia brain damage to Alzheimer's disease: a bioinformatics and experimental study.","date":"2025","source":"Frontiers in aging neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/39872979","citation_count":3,"is_preprint":false},{"pmid":"41331534","id":"PMC_41331534","title":"E3 ligase AREL1 controls perinuclear localization of lysosomes and supports Purkinje cell survival.","date":"2025","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/41331534","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.06.02.25328820","title":"Whole-genome sequencing study of 488,888 individuals identifies rare variants and genes associated with glaucoma","date":"2025-06-03","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.02.25328820","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":14452,"output_tokens":3119,"usd":0.04507,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10519,"output_tokens":3545,"usd":0.07061,"stage2_stop_reason":"end_turn"},"total_usd":0.11568,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2013,\n      \"finding\": \"AREL1 is a cytosolic HECT-family E3 ubiquitin ligase that interacts with and ubiquitinates IAP antagonists SMAC, HtrA2, and ARTS specifically after apoptotic stimulation releases them from mitochondria into the cytosol, promoting their degradation and thereby suppressing caspase-3 cleavage, XIAP degradation, and apoptosis.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays in cells, siRNA knockdown with apoptosis readouts (caspase-3 cleavage, XIAP degradation), subcellular fractionation/localization\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus functional knockdown with defined apoptosis phenotype, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"23479728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"AREL1 HECT E3 ligase preferentially assembles K33- and K11-linked polyubiquitin chains in vitro.\",\n      \"method\": \"In vitro ubiquitination assay using purified AREL1 combined with linkage-selective DUBs; mass spectrometry to confirm chain linkage\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with purified enzyme, confirmed by independent study (PMID:25752577), replicated across two labs\",\n      \"pmids\": [\"25723849\", \"25752577\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"AREL1 assembles K11/K33-linked ubiquitin chains, and in combination with linkage-selective DUBs can be used to generate pure K33-linked chains; these chains adopt an open, dynamic solution conformation.\",\n      \"method\": \"In vitro ubiquitination assay, mass spectrometry for linkage determination, NMR solution studies\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with purified components, replicated across two labs (PMID:25723849)\",\n      \"pmids\": [\"25752577\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"AREL1 (FIEL1/KIAA0317) ubiquitinates the SUMO E3 ligase PIAS4, targeting it for proteasomal degradation via a double-locking mechanism requiring PKCζ-mediated phosphorylation of PIAS4 and GSK3β-mediated phosphorylation of FIEL1, thereby potentiating TGF-β signaling and promoting pulmonary fibrosis.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, phosphorylation assays with kinase inhibitors/knockdown, overexpression and knockdown in cells and bleomycin murine fibrosis model\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, in vivo mouse model, site-specific phosphorylation mechanism defined, small molecule inhibitor validation, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"27162139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"KIAA0317 (AREL1) mediates the ubiquitination and proteasomal degradation of SOCS2, exacerbating proinflammatory cytokine signaling; KIAA0317 knockout mice are resistant to LPS-induced pulmonary inflammation, and a small molecule inhibitor (BC-1365) prevents SOCS2 degradation and attenuates lung inflammation in vivo.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, KIAA0317 knockout mice, LPS and P. aeruginosa lung inflammation models, small molecule inhibitor\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO mouse model with defined inflammatory phenotype, in vivo pharmacological validation, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"31578312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structure of the extended HECT domain of AREL1 (aa 436–823) at 2.4 Å resolution reveals an inverted T-shaped bilobed conformation with a unique loop (aa 567–573) absent in all other HECT members; the N-terminal extended region (aa 436–482) is indispensable for HECT domain stability and activity. AREL1 ubiquitinates SMAC primarily on Lys62 and Lys191. The AREL1 HECT domain assembles K33-, K48-, and K63-linked chains; E701A substitution increases autopolyubiquitination and SMAC ubiquitination, while deletion of the C-terminal three residues abrogates autoubiquitination and reduces SMAC ubiquitination.\",\n      \"method\": \"X-ray crystallography (2.4 Å HECT domain; 2.8 Å SMAC tetramer), in vitro ubiquitination assays, active-site mutagenesis (E701A, C-terminal deletion), ubiquitin variant inhibitor assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus in vitro reconstitution plus active-site mutagenesis in a single study\",\n      \"pmids\": [\"31732561\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"AREL1 interacts with Metaxin 2 (MTX2) via the C-terminal domain of MTX2 (distinct from the N-terminal domain that binds MTX1) and ubiquitinates MTX2, promoting its proteasomal degradation; catalytically inactive AREL1-C790A does not degrade MTX2. By degrading MTX2, AREL1 inhibits TNF-induced necroptosis.\",\n      \"method\": \"Co-immunoprecipitation with domain-mapping constructs, AREL1 catalytic mutant (C790A), siRNA knockdown, necroptosis assay (TNF stimulation)\",\n      \"journal\": \"Experimental and therapeutic medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — catalytic mutant used to confirm E3 dependence, domain-mapping Co-IP, single lab\",\n      \"pmids\": [\"34584540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"AREL1 and TRIP12 E3 ligases, together with UBE2L3, add K27-, K29-, and K33-linked polyubiquitin chains to pro-IL-1β, promoting its proteasomal degradation and thereby limiting inflammasome-driven mature IL-1β production and neutrophilic inflammation.\",\n      \"method\": \"RNAi screen, ubiquitination assays, Ube2l3 knockout mice, macrophage inflammasome activation assays, mass spectrometry for chain linkage\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — unbiased RNAi screen, in vivo KO mouse model, mass spectrometry chain-linkage determination, multiple orthogonal methods\",\n      \"pmids\": [\"37474493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"KIAA0317 (AREL1) ubiquitinates SOCS1 and promotes its proteasomal degradation, thereby dysregulating JAK/STAT inflammatory signaling in the colon; modulation of SOCS1 protein levels markedly affects colonic inflammatory responses.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, protein-protein interaction domain characterization, siRNA knockdown with JAK/STAT signaling readouts\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with mechanism characterization, functional signaling readout, single lab\",\n      \"pmids\": [\"36938956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"AREL1 interacts with SMAC in TGF-β-treated HUVECs and its overexpression inhibits caspase-3 and caspase-9 activation and apoptosis; miR-320b suppresses AREL1 expression, and AREL1 overexpression rescues miR-320b-induced apoptosis.\",\n      \"method\": \"Co-immunoprecipitation, overexpression, caspase activity assays, miRNA mimic/inhibitor transfection in HUVECs\",\n      \"journal\": \"Journal of biochemical and molecular toxicology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP and overexpression experiment, single lab, no mutagenesis\",\n      \"pmids\": [\"37522329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ER-resident AREL1 establishes membrane contacts between the ER and lysosomes by directly interacting with the Voa subunit of V-ATPase. AREL1 catalyzes K33-linked polyubiquitylation of the V-ATPase V1B2 subunit, inducing its binding to perinuclear ER-localized UBAC2, thereby promoting perinuclear lysosome clustering, lysosomal acidification, and degradative capacity. Loss of AREL1 increases peripheral lysosomes with partially assembled V-ATPase, elevated luminal pH, and reduced degradation. Arel1 knockout mice develop age-dependent Purkinje cell loss, ataxia, motor impairment, and lysosomal dysfunction (lipofuscin accumulation). The deubiquitylase ZRANB1 antagonizes AREL1-mediated V1B2 ubiquitylation.\",\n      \"method\": \"Co-immunoprecipitation, in vitro ubiquitination assays with linkage identification, live-cell imaging and fractionation for lysosome positioning, lysosomal pH measurements, Arel1 knockout mice with behavioral phenotyping and histology, ZRANB1 knockdown\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods including in vitro ubiquitination, structural contacts, KO mouse model with defined neurological phenotype, identification of writer-eraser pair (AREL1/ZRANB1), single study with comprehensive mechanistic validation\",\n      \"pmids\": [\"41331534\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"AREL1 is an ER-resident HECT E3 ubiquitin ligase that preferentially assembles K33- and K11-linked (and also K27/K29) polyubiquitin chains on diverse substrates including IAP antagonists (SMAC, HtrA2, ARTS), PIAS4, SOCS1, SOCS2, MTX2, pro-IL-1β, and the V-ATPase V1B2 subunit, thereby suppressing apoptosis, modulating cytokine/TGF-β signaling, limiting inflammasome-driven inflammation, and—via a newly defined AREL1-UBAC2-V-ATPase axis—controlling perinuclear lysosomal positioning and acidification that is required for Purkinje cell survival in vivo.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"AREL1 is a HECT-family E3 ubiquitin ligase that preferentially assembles non-canonical K33- and K11-linked (and also K27/K29) polyubiquitin chains to control apoptosis, inflammatory signaling, and lysosomal organization [#1, #2]. Crystallographic analysis of its extended HECT domain reveals an inverted T-shaped bilobed fold with a unique loop absent from other HECT members and an N-terminal extension required for catalytic activity, with catalysis depending on its C-terminal active-site residues [#5]. Its earliest defined role is anti-apoptotic: upon apoptotic stimulation, AREL1 binds and ubiquitinates the cytosolic IAP antagonists SMAC, HtrA2, and ARTS to drive their degradation, thereby blocking caspase-3 activation [#0, #5]. AREL1 additionally degrades regulatory substrates across signaling pathways—PIAS4 to potentiate TGF-\\u03b2 signaling and pulmonary fibrosis [#3], SOCS1 and SOCS2 to amplify JAK/STAT and proinflammatory cytokine signaling [#4, #8], MTX2 to restrain TNF-induced necroptosis [#6], and pro-IL-1\\u03b2 (with TRIP12 and UBE2L3) to limit inflammasome-driven inflammation [#7]. As an ER-resident ligase, AREL1 establishes ER\\u2013lysosome contacts via the V-ATPase Voa subunit and K33-ubiquitinates the V1B2 subunit, recruiting UBAC2 to promote perinuclear lysosome clustering, V-ATPase assembly, and acidification; this activity, antagonized by the deubiquitylase ZRANB1, is required for Purkinje cell survival, as Arel1 knockout mice develop age-dependent ataxia and lysosomal dysfunction [#10].\",\n  \"teleology\": [\n    {\n      \"year\": 2013,\n      \"claim\": \"Established AREL1 as a functional E3 ligase with a defined biological output by showing it targets IAP antagonists for degradation to suppress apoptosis.\",\n      \"evidence\": \"Co-IP, cellular ubiquitination assays, and siRNA knockdown with caspase-3/XIAP apoptosis readouts\",\n      \"pmids\": [\"23479728\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Chain linkage type not yet defined\", \"Ubiquitination sites on substrates not mapped\", \"Single lab, no structural basis\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined the biochemical signature of AREL1 by demonstrating it preferentially builds non-canonical K33- and K11-linked chains, distinguishing it from canonical degradative ligases.\",\n      \"evidence\": \"In vitro reconstitution with purified enzyme, linkage-selective DUBs, mass spectrometry, and NMR of chain conformation; replicated across two labs\",\n      \"pmids\": [\"25723849\", \"25752577\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Physiological substrates of K33/K11 chains not linked to specific outcomes here\", \"Connection between linkage type and proteasomal fate unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Extended AREL1 beyond apoptosis by showing it degrades PIAS4 through a phosphorylation-gated double-lock mechanism to potentiate TGF-\\u03b2-driven fibrosis.\",\n      \"evidence\": \"Co-IP, ubiquitination and kinase-dependent phosphorylation assays, bleomycin murine fibrosis model with small-molecule inhibitor\",\n      \"pmids\": [\"27162139\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Chain linkage on PIAS4 not specified\", \"Generalizability of phospho-gating to other substrates unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed AREL1 amplifies inflammatory signaling by degrading SOCS2, and that genetic or pharmacological inhibition is protective in vivo, establishing therapeutic relevance.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, KIAA0317 knockout mice in LPS/P. aeruginosa lung inflammation models, BC-1365 inhibitor\",\n      \"pmids\": [\"31578312\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Linkage type on SOCS2 not defined\", \"Whether SOCS2 degradation is the sole driver of the inflammatory phenotype unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Provided the structural basis for AREL1 catalysis, identifying a unique HECT-domain loop, an essential N-terminal extension, and the SMAC ubiquitination sites and active-site residues.\",\n      \"evidence\": \"X-ray crystallography of HECT domain and SMAC tetramer, active-site mutagenesis (E701A, C-terminal deletion), ubiquitin-variant inhibitor assay\",\n      \"pmids\": [\"31732561\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Full-length structure including N-terminal substrate-recognition region not resolved\", \"Structural determinant of K33/K11 linkage selectivity not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Added necroptosis control to AREL1's repertoire by showing catalysis-dependent degradation of MTX2 restrains TNF-induced necroptosis.\",\n      \"evidence\": \"Domain-mapping Co-IP, catalytic mutant (C790A), siRNA knockdown, TNF necroptosis assay\",\n      \"pmids\": [\"34584540\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"In vivo relevance not tested\", \"Chain linkage on MTX2 not characterized\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated AREL1 acts as a multi-ligase that, with TRIP12 and UBE2L3, K27/K29/K33-ubiquitinates pro-IL-1\\u03b2 to dampen inflammasome output, and separately degrades SOCS1 to dysregulate colonic JAK/STAT signaling.\",\n      \"evidence\": \"RNAi screen, ubiquitination assays with MS linkage determination, Ube2l3 knockout mice, macrophage inflammasome assays; Co-IP and JAK/STAT readouts for SOCS1\",\n      \"pmids\": [\"37474493\", \"36938956\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Relative contributions of AREL1 versus TRIP12 to pro-IL-1\\u03b2 turnover not partitioned\", \"SOCS1 study is single-lab Medium-confidence without in vivo model\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Redefined AREL1 as an ER-resident organizer of ER\\u2013lysosome contacts, linking its K33-ubiquitination of V-ATPase V1B2 to lysosome positioning, acidification, and Purkinje cell survival.\",\n      \"evidence\": \"Co-IP, in vitro ubiquitination with linkage ID, live-cell imaging/fractionation for lysosome positioning, lysosomal pH measurement, Arel1 knockout mice with behavior and histology, ZRANB1 knockdown\",\n      \"pmids\": [\"41331534\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Mechanism by which V1B2 ubiquitination drives UBAC2 binding and clustering at atomic level unresolved\", \"Relationship between this ER-resident pool and prior cytosolic/apoptotic roles unclear\", \"Whether neurodegeneration is purely lysosomal or involves other substrates not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How AREL1 selects among its many substrates, and how its non-canonical chain linkages dictate proteasomal degradation versus signaling/contact-site assembly, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"No unifying substrate-recognition logic established across SMAC, PIAS4, SOCS1/2, MTX2, pro-IL-1\\u03b2, and V1B2\", \"Functional distinction between K33 chains that target degradation versus those that nucleate ER-lysosome contacts unclear\", \"Reconciliation of cytosolic versus ER-resident localization across studies not addressed\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [0, 1, 3, 5, 10]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 3, 6, 7, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 6]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 7, 8]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 8]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [1, 5]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"SMAC\", \"PIAS4\", \"SOCS1\", \"SOCS2\", \"MTX2\", \"UBAC2\", \"ZRANB1\", \"TRIP12\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}